Valuation: Alvotech

Market Cap 2.11B 1.86B 1.76B 1.6B 3B 203B 3.03B 21.16B 8.16B 104B 7.93B 7.76B 333B P/E 2026 *
114x
P/E 2027 * 19.9x
Enterprise Value 3.19B 2.81B 2.66B 2.42B 4.53B 306B 4.57B 31.95B 12.31B 156B 11.98B 11.72B 503B EV / Sales 2026 *
4.84x
EV / Sales 2027 * 4.09x
Free-Float
39.95%
Yield 2026 *
-
Yield 2027 * -
1 day-3.74%
1 week+1.37%
Current month+14.07%
1 month+19.60%
3 months+59.14%
6 months+90.35%
Current year+15.40%
1 week 5.67
Extreme 5.67
6.17
1 month 4.9
Extreme 4.9
6.17
Current year 2.94
Extreme 2.94
6.17
1 year 2.94
Extreme 2.94
9.04
3 years 2.94
Extreme 2.94
18
5 years 2.94
Extreme 2.94
18
10 years 2.94
Extreme 2.94
18
Manager TitleAgeSince
Chief Executive Officer 55 28/02/2026
Director of Finance/CFO 48 09/07/2025
Chief Tech/Sci/R&D Officer - 31/12/2022
Director TitleAgeSince
Chairman 56 31/12/2018
Director/Board Member 64 31/12/2018
Director/Board Member 58 31/12/2018
Date Insider Type Main position Quantity % Market Cap. Importance
01/04/26 Free

Chief Executive Officer

117,271 0.0355%
01/04/26 Sell

Founder

318,000 0.0963%
01/04/26 Buy

Founder

318,000 0.0963%
Change 5-day change 1-year change 3-year change Capi.($)
-3.74%+1.37%-29.52%-35.09% 2.2B
-0.03%+3.77%+12.35%+37.22% 49.06B
-0.73%-0.41%+48.84%+36.72% 44.6B
+1.36%+6.03%+343.85%+638.73% 43.24B
-0.47%-0.76%+9.75%+103.07% 41.73B
+0.34%+0.22%+5.18%+47.36% 29.93B
+1.00%-1.28%+24.23%+156.93% 17.19B
-3.20%-3.50%+25.33%+42.43% 15.54B
-2.94%+6.98%+5.10% - 15.35B
-0.86%-4.00% - - 15.11B
Average -0.93%+1.21%+49.46%+128.42% 27.39B
Weighted average by Cap. -0.30%+1.80%+73.55%+164.61%

Financials

2026 *2027 *
Net sales 659M 582M 551M 499M 936M 63.27B 945M 6.6B 2.55B 32.31B 2.48B 2.42B 104B 776M 685M 648M 587M 1.1B 74.43B 1.11B 7.77B 2.99B 38.01B 2.91B 2.85B 122B
Net income 30.36M 26.79M 25.35M 22.99M 43.1M 2.91B 43.53M 304M 117M 1.49B 114M 112M 4.79B 109M 96.29M 91.1M 82.62M 155M 10.47B 156M 1.09B 421M 5.35B 410M 401M 17.2B
Net Debt 1.08B 950M 899M 815M 1.53B 103B 1.54B 10.79B 4.16B 52.77B 4.04B 3.96B 170B 1.06B 933M 883M 801M 1.5B 101B 1.52B 10.59B 4.08B 51.8B 3.97B 3.88B 167B
Logo Alvotech
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
Employees
1,279
Date Price Change Volume
29/09/26 US$5.920 -3.74% 1,169,749
28/09/26 US$6.150 +6.96% 1,436,374
25/09/26 US$5.750 -2.21% 705,189
24/09/26 US$5.880 +1.20% 1,198,733
23/09/26 US$5.810 -0.51% 774,267
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
5.920USD
Average target price
6.800USD
Spread / Average Target
+14.86%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALVO Stock